{"id":6794,"date":"2024-05-13T12:30:00","date_gmt":"2024-05-13T12:30:00","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/correction-update-of-q1-2024\/"},"modified":"2024-05-13T12:30:00","modified_gmt":"2024-05-13T12:30:00","slug":"correction-update-of-q1-2024","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/correction-update-of-q1-2024\/","title":{"rendered":"Correction\/Update of Q1 – 2024"},"content":{"rendered":"
\n

Scandinavian Real Heart publishes an updated version of the Q1 report.
The new details in the update are:
Information on change in equity.
Calculated number of shares considering the future dilution from existing warrant programs.
Information on existing warrant program\/incentive program for employees.
\u00a0
The above is information that has been communicated earlier, but has now been added to the report.<\/p>\n<\/div>\n

\n

For more information, please contact:<\/strong>
Ina Laura Perkins, CEO
Phone: +46 (0) 70 406 49 21\u00a0
E-mail: inalaura.perkins@realheart.se<\/a>
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se<\/a><\/p>\n<\/div>\n

\n

About Us<\/strong>
Scandinavian Real Heart is active in medical technology. The company conducts research and development in observations of the physiology of the heart. The development of the company's product, a complete artificial heart (TAH), takes place in collaboration with cardiac surgeons, researchers and engineers. The focus is on developing patented solutions that can imitate the blood circulation of the natural human heart. The solutions are intended for use by patients diagnosed with heart failure.<\/p>\n<\/div>\n

\n

Attachments<\/strong>
Realheart Q1 2024 ENG 240513<\/a><\/p>\n<\/div>\n